CureVac NV (WBO:CVAC) Dividend Payout Ratio : 0.00 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is CureVac NV Dividend Payout Ratio?

CureVac NV's dividend payout ratio for the months ended in Dec. 2023 was 0.00.

The historical rank and industry rank for CureVac NV's Dividend Payout Ratio or its related term are showing as below:

WBO:CVAC's Dividend Payout Ratio is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.43
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2024-05-03), the Dividend Yield % of CureVac NV is 0.00%.

CureVac NV's Dividends per Share for the months ended in Dec. 2023 was €0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

CureVac NV Dividend Payout Ratio Historical Data

The historical data trend for CureVac NV's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CureVac NV Dividend Payout Ratio Chart

CureVac NV Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dividend Payout Ratio

Get a 7-Day Free Trial

CureVac NV Quarterly Data
	Dec18	Mar19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Dividend Payout Ratio	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of CureVac NV's Dividend Payout Ratio

For the Biotechnology subindustry, CureVac NV's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CureVac NV's Dividend Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CureVac NV's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where CureVac NV's Dividend Payout Ratio falls into.

CureVac NV Dividend Payout Ratio Calculation

Dividend payout ratio measures the percentage of the company's earnings paid out as dividends.

CureVac NV's Dividend Payout Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (A: Dec. 2023 )	/	EPS without NRI (A: Dec. 2023 )
	=	0	/	-1.188
	=	N/A

CureVac NV's Dividend Payout Ratio for the quarter that ended in Dec. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Dec. 2023 )	/	EPS without NRI (Q: Dec. 2023 )
	=	0	/	-0.394
	=	N/A

CureVac NV (WBO:CVAC) Dividend Payout Ratio Explanation

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

CureVac NV Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of CureVac NV's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

CureVac NV (WBO:CVAC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CureVac NV (WBO:CVAC) » Definitions » Dividend Payout Ratio

Comparable Companies

Traded in Other Exchanges

CVAC:USA CVAC:Mexico 1CVAC:Italy 0A9E:UK 5CV:Germany

Address

Friedrich-Miescher-Strasse 15, Tubingen, BW, DEU, 72076

Website

https://www.curevac.com

CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.